NCT01987349已完成4 期
Protective Mechanisms Against a Pandemic Respiratory Virus: B- Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 1, 2009
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 2
- 主要终点
- Number of Participants From Each Arm Who Received Influenza Vaccine Vaccine
研究概览
简要总结
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
详细描述
The investigators plan to study the response to different influenza vaccines much more broadly and deeply across different age groups and with different vaccine modalities and to probe the influence of genetics on these responses using monozygotic and dizygotic twins.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 8 Years 至 100 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Otherwise healthy, ambulatory children or adults, ages 8-17 years (identical twin pairs), 18-30 years (identical or fraternal twin pairs), 40-49 years (identical or fraternal twin pairs) or 70-100 years (twin or non-twin adults).
- •Willing to complete the informed consent process.
- •Availability for follow-up for the planned duration of the study at least 28 days after immunization.
- •Acceptable medical history and vital signs.
- •Negative urine pregnancy test for women of childbearing potential
- •If the subject is female and of childbearing potential, she must use an acceptable method of contraception and not become pregnant for the duration of the study. (Acceptable contraception includes implants, injectables, combined oral contraceptives, effective intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner).
排除标准
- •Prior vaccination with TIV or LAIV in Fall 2009
- •Allergy to egg or egg products, or to vaccine components, including gentamicin, gelatin, arginine or MSG (for LAIV only), or thimerosal (TIV multidose vials only).
- •Life-threatening reactions to previous influenza vaccinations
- •Asthma (LAIV groups only)
- •Active systemic or serious concurrent illness, including febrile illness on the day of vaccination
- •History of immune deficiency
- •Known or suspected impairment of immunologic function, including, but not limited to, clinically significant liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease, blood pressure >150/95 at screening, or any other chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
- •Hospitalization in the past year for congestive heart failure or emphysema.
- •Chronic Hepatitis B or C
- •Recent or current use of immunosuppressive medication, including glucocorticoids (corticosteroid nasal sprays are permissible).
- •Subjects in close contact with anyone who has a severely weakened immune system should not receive LAIV.
- •Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors such as breast cancer or prostate cancer with recurrence in the past year, and any hematologic cancer such as leukemia).
- •Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
- •History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year
- •Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin, Plavix, Aggrenox may be acceptable after review by investigator.
- •Receipt of blood or blood products within the past 6 months
- •Medical or psychiatric condition or occupational responsibilities that preclude subject compliance with the protocol
- •Inactivated vaccine 14 days prior to vaccination
- •Live, attenuated vaccine within 60 days of vaccination
- •History of Guillain-Barre Syndrome
- •Pregnant or lactating woman
- •Use of investigational agents within 30 days prior to enrollment
- •Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment
- •Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.
结局指标
主要结局
Number of Participants From Each Arm Who Received Influenza Vaccine Vaccine
时间窗: Day 0 to 28
次要结局
- Number of Participants With Related Adverse Events(Day 0 to 28 post-immunization)
研究者
Cornelia L. Dekker
Professor, Pediatrics
Stanford University
研究点 (2)
Loading locations...
相似试验
已完成
4 期
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010InfluenzaNCT03022396Stanford University82
终止
不适用
PET-CT Scans in Healthy Volunteers After Flu VaccinationFluNCT00769002Hackensack Meridian Health18
已完成
1 期
Heterosubtypic Immune Responses to Influenza in Older PeopleInfluenzaNCT00798343University Hospitals, Leicester292
已完成
不适用
A Systematic Review of Studies of the Effect of Influenza Vaccine Against Mismatched StrainsInfluenzaNCT01416597GlaxoSmithKline1
已完成
2 期
Comparison of Delivery Routes of Flu Vaccine in AdultsInfluenzaNCT00170547National Institute of Allergy and Infectious Diseases (NIAID)1,597